This review summarizes an expanding body of knowledge indicating that failure to resolve
inflammation and altered immune processes underlie the development of pulmonary arterial …

Numerous molecular abnormalities have been described in pulmonary arterial hypertension
(PAH), complicating the translation of candidate therapies to patients because, typically, 1 …

Inflammation triggers pulmonary vascular remodelling. Ferroptosis, a nonapoptotic form of
cell death that is triggered by iron-dependent lipid peroxidation and contributes to the …

Pulmonary arterial hypertension (PAH) is a progressive vascular disease with a high
mortality rate. It is characterized by an occlusive vascular remodeling due to a pro …

Rationale: Accumulating evidence implicates inflammation in pulmonary arterial
hypertension (PAH) and therapies targeting immunity are under investigation, although it …

Pulmonary arterial hypertension (PAH) describes a group of conditions with a common
hemodynamic phenotype of increased pulmonary artery pressure, driven by progressive …

Pulmonary arterial hypertension (PAH) is a vascular remodeling disease of the lungs
resulting in heart failure and premature death. Although, until recently, it was thought that …

Mitochondrial dysfunction, inflammation, and mutant bone morphogenetic protein receptor 2
(BMPR2) are associated with pulmonary arterial hypertension (PAH), an incurable disease …

Background—Pulmonary arterial hypertension (PAH) is associated with sustained
inflammation known to promote DNA damage. Despite these unfavorable environmental …

Pulmonary hypertension is an “umbrella term” used for a spectrum of entities resulting in an
elevation of the pulmonary arterial pressure. Clinical symptoms include dyspnea and fatigue …